Notice of Interim Results

RNS Number : 6329W

Ergomed plc

20 August 2020

 

PRESS RELEASE

Notice of Interim Results

Guildford, UK - 20 August 2020 : Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialized services to the pharmaceutical industry, will announce its interim results for the six months ending 30 June 2020 on 22 September 2020.

Miroslav Reljanović, Executive Chairman and Richard Barfield, Chief Financial Officer will host a virtual presentation and conference call for analysts at 9am BST on the day of the results.

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited	Tel: [phone]
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Sue Stuart	[e-mail]
Matthew Neal / Olivia Manser
MC Services - for Continental European enquiries	Tel: [phone]
Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognized specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com .

 

END

 

 

NORBLGDIRUBDGGC